Clinical uses of 1-alpha-hydroxycholecalciferol

Current Vascular Pharmacology

Volumn 12, Issue 2, 2014, Pages 300-305

  Vervloet, Marc ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alfacalcidol; Bone mineral density; Cardiovascular disease; Chronic kidney disease; CKD MBD; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL RECEPTOR; HYDROXYCOLECALCIFEROL; PARATHYROID HORMONE;

ANIMAL; BLOOD; BONE DENSITY; CARDIOVASCULAR DISEASES; DRUG EFFECTS; HUMAN; PHYSIOLOGY;

ANIMALS; BONE DENSITY; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYCHOLECALCIFEROLS; PARATHYROID HORMONE; RECEPTORS, CALCITRIOL;

EID: 84924481653     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990132     Document Type: Review

References (80)

1. Schnoes HK, DeLuca HF. Synthetic analogs of 1alpha,25-dihydroxyvitamin D3 and their biological activity. Vitam Horm 1974; 32: 385-406.
2. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabolism. Endocrinol Metab Clin North Am 2010; 39(2): 243-53.
3. Norman AW, Ishizuka S, Okamura WH. Ligands for the vitamin Dendocrine system: different shapes function as agonists and antagonists for genomic and rapid response receptors or as a ligand for the plasma vitamin D binding protein. J Steroid Biochem Mol Biol 2001; 76(1-5): 49-59.
4. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16(2): 200-257.
5. Michaud J, Naud J, Ouimet D, et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2010; 21(9): 1488-1497.
6. Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001; 2(2): 165-183.
7. Brandi L, Egfjord M, Olgaard K. Pharmacokinetics of1, 25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. Nephrol Dial Transplant 2002; 17(5): 829-842.
8. Mitwalli AH, Alam AA. Intermittent oral versus intravenous alfacalcidol in dialysis patients. Saudi J Kidney Dis Transpl 2000; 11(2): 174-180.
9. Carpenter KJ, Zhao L. Forgotten mysteries in the early history of vitamin D. J Nutr 1999; 129(5): 923-927.
10. Shiraishi A, Takeda S, Masaki T, et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000; 15(4): 770-779.
11. Shiraishi A, Ito M, Hayakawa N, Kubota N, Kubodera N, Ogata E. Calcium supplementation does not reproduce the pharmacological efficacy of alfacalcidol for the treatment of osteoporosis in rats. Calcif Tissue Int 2006; 78(3): 152-161.
12. Shiraishi A, Higashi S, Masaki T, et al. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 2002; 71(1): 69-79.
13. Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001; 33(1): 19-24.
14. Kasukawa Y, Miyakoshi N, Maekawa S, Nozaka K, Noguchi H, Shimada Y. Effects of alfacalcidol on muscle strength, muscle fatigue, and bone mineral density in normal and ovariectomized rats. Biomed Res 2010; 31(5): 273-279.
15. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18(2): 343-351.
16. Testerink J, Degens H, Rittweger J, Shiraishi A, Jaspers RT, de HA. Effects of alfacalcidol on the contractile properties of the gastrocnemius medialis muscle in adult and old rats. J Physiol Pharmacol 2011; 62(1): 111-118.
17. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78(5): 1296-1301.
18. Szabo A, Merke J, Beier E, Mall G, Ritz E. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35(4): 1049-1056.
19. Goldenberg MM. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clin Ther 1999; 21(3): 432-441.
20. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30(1): 105-112.
21. Brown AJ, Ritter CS, Knutson JC, Strugnell SA. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrol Dial Transplant 2006; 21(3): 644-650.
22. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279(16): 16754-16766.
23. Krog M, Ejerblad S, Eriksson I, Johansson H. Arterial calcifications in uraemic rats treated with 1-alpha-hydroxycholecalciferol and parathyroidectomy. Scand J Urol Nephrol 1984; 18(3): 227-239.
24. Krog M, Ejerblad S, Ericsson JL. Uraemic and 1-alphahydroxycholecalciferol induced aortic lesions. Exp Pathol 1988; 35(2): 101-114.
25. Saupe J, Hirschberg R, Hofer W, et al. Effect of long-term administration of 1,25-dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 on the calcium content of the aorta, heart and kidney of normal and uremic rats. Nephron 1986; 43(4): 290-292.
26. Al-Badr W, Martin KJ. Vitamin D and kidney disease. Clin J Am Soc Nephrol 2008; 3(5): 1555-1560.
27. Saha H. Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol 1994; 41(5): 290-296.
28. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011; 79(7): 715-729.
29. Christensen EI, Willnow TE. Essential role of megalin in renal proximal tubule for vitamin homeostasis. J Am Soc Nephrol 1999; 10(10): 2224-2236.
30. Doorenbos CR, de Cuba MM, Vogt L, et al. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. J Steroid Biochem Mol Biol 2012; 128(1-2): 56-61.
31. Ringe JD, Farahmand P, Schacht E, Rozehnal A. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 2007; 27(5): 425-434.
32. Barone A, Giusti A, Pioli G, et al. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc 2007; 55(5): 752-757.
33. Ringe JD, Schacht E. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Rheumatol Int 2007; 28(2): 103-111.
34. O'Donnell S, Moher D, Thomas K, Hanley DA, Cranney A. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 2008; 26(6): 531-542.
35. Scharla SH, Schacht E, Lempert UG. Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J Rheumatol Suppl 2005; 76: 26-32.
36. Brownjohn AM, Goodwin FJ, Hately W, Marsh FP, O’Riordan JL, Papapoulos SE. 1-alpha-hydroxycholecalciferol for renal osteodystrophy. Br Med J 1977; 2(6089): 721-723.
37. Juttmann JR, Birkenhager-Frenkel DH, Visser TJ, van KC, Birkenhager JC. Follow-up of long-term treatment of predialysis renal bone disease with 1-alpha-hydroxy-derivatives of vitamin D. J Steroid Biochem 1983; 19(1B): 511-516.
38. Sharman VL, Brownjohn AM, Goodwin FJ, et al. Long-term experience of alfacalcidol in renal osteodystrophy. Q J Med 1982; 51(203): 271-278.
39. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310(6976): 358-363.
40. McGregor MS, Rowe PA, Junor BJ. Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Monitoring the calcium-phosphate product is important. BMJ 1995; 311(6997): 124-125.
41. Fournier A, Esper NE, Moriniere P, Oprisiu R, Marie A. Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Questions remain over alfacalcidol's efficacy in preventing secondary hyperparathyroidism. BMJ 1995; 311(6997): 124-125.
42. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004; 19(4): 870-876.
43. Smets YF, de Fijter JW, Ringers J, Lemkes HH, Hamdy NA. Longterm follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantation. Kidney Int 2004; 66(5): 2070-2076.
44. Berczi C, Asztalos L, Kincses Z, et al. Comparison of calcium and alfacalcidol supplement in the prevention of osteopenia after kidney transplantation. Osteoporos Int 2003; 14(5): 412-417.
45. El-Husseini AA, El-Agroudy AE, El-Sayed M, Sobh MA, Ghoneim MA. A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents. Am J Transplant 2004; 4(12): 2052-2057.
46. El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 2004; 8(4): 357-361.
47. Trabulus S, Altiparmak MR, Apaydin S, Serdengecti K, Sariyar M. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. Transplant Proc 2008; 40(1): 160-166.
48. Brandi L, Daugaard H, Tvedegaard E, et al. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alphahydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 1992; 12(5): 311-318.
49. Gonzalez MT, Torregrosa JV, Colome E, Mendia A, Pavesi M. Efficacy of intravenous alfacalcidol in the treatment of secondary hyperparathyroidism in patients on hemodialysis. Nephron Clin Pract 2008; 108(2): c141-c147.
50. Reichel H. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease. Nephron Clin Pract 2010; 114(4): c268-c276.
51. Nishi H, Sato T, Kurihara T, Kurosawa T, Fukagawa M. Control of parathyroid function in patients with a short history of hemodialysis. Ther Apher Dial 2005; 9(1): 39-43.
52. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999; 73: S14-S19.
53. Moe S, Wazny LD, Martin JE. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. Can J Clin Pharmacol 2008; 15(1): e36-e43.
54. Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology (Carlton) 2011; 16(3): 277-284.
55. Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology (Carlton) 2011; 16(3): 277-284.
56. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63(4): 1483-1490.
57. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001; 38(5 Suppl 5): S51-S56.
58. Hansen D, Rasmussen K, Danielsen H, et al. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int 2011; 80(8): 841-850.
59. Lee WT, Padayachi K, Collins JF, Cundy T. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism. J Am Soc Nephrol 1994; 5(6): 1344-1348.
60. Tarrass F, Yazidi A, Sif H, Zamd M, Benghanem MG, Ramdani B. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease. Clin Nephrol 2006; 65(6): 415-418.
61. Brandenburg VM, Vervloet MG, Marx N. The role of vitamin D in cardiovascular disease: From present evidence to future perspectives. Atherosclerosis 2012; 225(2): 253-263.
62. Sugiura S, Inaguma D, Kitagawa A, et al. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 2010; 14(1): 43-50.
63. Ivarsen P, Povlsen JV, Christensen KL. Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study. Scand J Urol Nephrol 2012; 46(5): 381-388.
64. Tarrass F, Benjelloun M, Zamd M, et al. Heart valve calcifications in patients with end-stage renal disease: analysis for risk factors. Nephrology (Carlton) 2006; 11(6): 494-496.
65. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19(1): 179-184.
66. Vervloet MG, Twisk JW. Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data. Nephrol Dial Transplant 2009; 24(3): 703-706.
67. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16(4): 1115-1125.
68. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349(5): 446-456.
69. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70(4): 771-780.
70. Jean G, Lataillade D, Genet L, et al. Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study. Nephron Clin Pract 2011; 118(2): c204-c210.
71. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; (4): CD008175.
72. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Schohn D, Chuet C. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant 1997; 12(3): 514-518.
73. Huraib S, Tanimu D, bu-Romeh S, et al. Effect of intravenous alfacalcidol on lymphocyte phenotyping in hemodialysis patients. Am J Kidney Dis 1998; 32(6): 1036-1040.
74. Prie D, Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol 2010; 5(9): 1717-1722.
75. Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 2012; 27(6): 2263-2269.
76. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82(7): 737-747.
77. Coburn JW, Maung HM. Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. Kidney Int Suppl 2003; (85): S49-S53.
78. Hansen D. A randomised clinical study of alfacalcidol and paricalcitol. Dan Med J 2012; 59(2): B4400.
79. Brown AJ, Coyne DW. Bioavailable vitamin D in chronic kidney disease. Kidney Int 2012; 82(1): 5-7.
80. Bhan I, Powe CE, Berg AH, et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 2012; 82(1): 84-89.